Table 2.
Distribution of familial and sporadic cases, affected and healthy family members in our study group compared to other populations in previous studies.
| IgAD (n = 70) | Selective IgAD (n = 36) | Partial IgAD (n = 34) | CVID (n = 40) | Total Turkish CVID and IgAD patients | Iranian (Aghamohammadi et al.9) Study CVID (n = 23) |
Iranian (Rezaei et al.10) Study CVID (n = 23) and IgAD (n = 14) (Total = 37) |
Spanish (Soler-Palacín et al.11) study IgAD (n = 42) |
|
|---|---|---|---|---|---|---|---|---|
| FC | 24/70 (34.2%) | 10/36 (27.7%) | 14/34 (41.1%) | 13/40 (32.5%) | 33.6% | ND | ND | 31% |
| SC | 46/70 (65.8%) | 26/36 (72.3%) | 20/34 (58.9%) | 27/40 (67.5%) | 66.4% | ND | ND | 69% |
| Number of FDRs | 162 | 81 | 81 | 80 | 251 | 64 | 106 | 88 |
| A-FDR | 31/162 (19.1%) | 16/84 (19.0%) | 15/78 (19.2%) | 17/89 (19.1%) | 19.1% | 20% | 11.3% | 16% |
| Affected mothers | 13 | 7 | 6 | 6 | 19.7% (19/96) | 11% | 2.9% | 22% |
| Affected fathers | 6 | 0 | 6 | 12 | 18.5% (18/97) | 17.6% | 2.8% | 10% |
| Affected siblings | 5 | 2 | 3 | 6 | 18.9% (11/58) | 22% | 25% | 14.5% |
IgAD, immunoglobulin A deficiency; CVID, common variable immunodeficiency; FC, familial case; SC, sporadic case; FDR, first-degree relative; A-FDR, affected FDR; ND, not determined.